What are the key considerations and emerging trends for IDNs as they work with their plans on 2020 formulary decision-making and selections? Elizabeth Oyekan breaks this down and focuses on the pressure points.
Offensive or Defensive Drug Cost Strategies: Which Will Give Payers and Health Systems the Best Chance to Lower Drug Costs?
When it comes to winning in the effort to reduce rising drug costs, there are new offensive and defensive strategies in play. What works better in pharma? Does a good offense beat a good defense?
After 6 years, CMS is proposing changes to the MSSP, with ACOs set to take on additional risk in an effort to reduce the cost of care to the delivery system and Medicare beneficiaries. Precision’s Elizabeth Oyekan examines the proposed Pathway to Success rule and its central tenet, the adoption of 2-sided risk models.
Elizabeth Oyekan, Senior Director, Quality and Population Health Solutions, explores the evolution of medical benefit management strategies and helps manufacturers understand where their products fit on clinical pathways—and how those pathways may differ by vendor.